ClinicalTrials.gg

Program

ASKC202

A development code. Also written as “ASKC202+ Limertinib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Beijing Aosaikang Pharmaceutical.

Furthest: phase 3, since Jul 31, 20253 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Aosaikang Pharmaceutical33 open or runningphase 3since Jul 31, 2025Mar 23, 2022Dec 2026phase 1 · NCT05306132

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 23, 2022First study: phase 1 study in Advanced Solid TumorFirst studyNCT05306132 · 150 planned · China
  2. Jul 31, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07109531 · 286 planned · China
  3. Oct 20, 2026Phase 3 study in EGFR Activating MutationNCT07897188 · 425 planned · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in Advanced Solid TumorNCT05306132
  2. Oct 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07109531
  3. Dec 30, 2030Primary completion: phase 3 study in EGFR Activating MutationNCT07897188

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07897188EGFR Activating Mutation · China3Not yet recruitingDec 30, 2030425
NCT07109531Carcinoma, Non-Small-Cell Lung · China3RecruitingOct 31, 2027286
NCT05306132Advanced Solid Tumor · China1RecruitingDec 2026150

How it is read

Names in the registry

  • “ASKC202”, 2 entries
  • “ASKC202+ Limertinib”, 1 entry

Codes read as this program: ASKC202.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.